Kijoeng Nam

1.5k total citations · 1 hit paper
22 papers, 603 citations indexed

About

Kijoeng Nam is a scholar working on Surgery, Oncology and Biotechnology. According to data from OpenAlex, Kijoeng Nam has authored 22 papers receiving a total of 603 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Surgery, 12 papers in Oncology and 10 papers in Biotechnology. Recurrent topics in Kijoeng Nam's work include Bladder and Urothelial Cancer Treatments (19 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Cancer Research and Treatments (10 papers). Kijoeng Nam is often cited by papers focused on Bladder and Urothelial Cancer Treatments (19 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Cancer Research and Treatments (10 papers). Kijoeng Nam collaborates with scholars based in United States, Japan and Canada. Kijoeng Nam's co-authors include Ashish M. Kamat, Ekta Kapadia, Hiroyuki Nishiyama, Tara L. Frenkl, Dean F. Bajorin, Ronald de Wit, Joost L. Boormans, Ho Kyung Seo, Petros Grivas and Eric A. Singer and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and The Journal of Urology.

In The Last Decade

Kijoeng Nam

21 papers receiving 594 citations

Hit Papers

Pembrolizumab monotherapy... 2021 2026 2022 2024 2021 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
    2021 329 citations Arjun Vasant Balar, Ashish M. Kamat et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kijoeng Nam United States 10 526 238 120 100 81 22 603
José Portillo Spain 6 590 1.1× 144 0.6× 72 0.6× 186 1.9× 69 0.9× 18 643
Vipulkumar Dadhania United States 7 377 0.7× 110 0.5× 126 1.1× 55 0.6× 144 1.8× 11 460
A P van der Meijden Netherlands 6 573 1.1× 82 0.3× 49 0.4× 242 2.4× 119 1.5× 10 643
Catalona Wj United States 8 330 0.6× 91 0.4× 87 0.7× 98 1.0× 111 1.4× 23 466
J.L.J. Vriesema Netherlands 13 270 0.5× 61 0.3× 85 0.7× 91 0.9× 42 0.5× 13 368
Spasenija Savic-Prince Switzerland 5 359 0.7× 161 0.7× 40 0.3× 81 0.8× 57 0.7× 6 438
Ch. Bouffioux Belgium 6 427 0.8× 60 0.3× 61 0.5× 157 1.6× 45 0.6× 7 469
Sameh Shamaa Egypt 11 125 0.2× 74 0.3× 90 0.8× 56 0.6× 37 0.5× 37 352
Timothy Brennan United States 6 287 0.5× 146 0.6× 221 1.8× 55 0.6× 82 1.0× 13 587
Cheryl L. Hayden United States 9 377 0.7× 113 0.5× 179 1.5× 78 0.8× 38 0.5× 13 549

Countries citing papers authored by Kijoeng Nam

Since Specialization
Citations

This map shows the geographic impact of Kijoeng Nam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kijoeng Nam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kijoeng Nam more than expected).

Fields of papers citing papers by Kijoeng Nam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kijoeng Nam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kijoeng Nam. The network helps show where Kijoeng Nam may publish in the future.

Co-authorship network of co-authors of Kijoeng Nam

This figure shows the co-authorship network connecting the top 25 collaborators of Kijoeng Nam. A scholar is included among the top collaborators of Kijoeng Nam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kijoeng Nam. Kijoeng Nam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shore, Neal D., Hiroyuki Nishiyama, Shahrokh F. Shariat, et al.. (2024). Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.. Journal of Clinical Oncology. 42(4_suppl). TPS722–TPS722. 2 indexed citations
2.
Nam, Kijoeng, et al.. (2024). Nonparametric analysis of delayed treatment effects using single‐crossing constraints. Biometrical Journal. 66(2). e2200165–e2200165.
3.
4.
Balar, Arjun Vasant, Ashish M. Kamat, Girish S. Kulkarni, et al.. (2021). Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. The Lancet Oncology. 22(7). 919–930. 329 indexed citations breakdown →
5.
Alva, Ajjai, Tibor Csőszi, Mustafa Özgüroğlu, et al.. (2021). Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology. 39(6_suppl). 439–439. 2 indexed citations
6.
Powles, Thomas, Tibor Csőszi, Mustafa Özgüroğlu, et al.. (2021). 1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.. Journal of Clinical Oncology. 39(6_suppl). 450–450. 10 indexed citations
7.
Özgüroğlu, Mustafa, Ajjai Alva, Tibor Csőszi, et al.. (2021). Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology. 39(6_suppl). 448–448. 2 indexed citations
8.
Balar, Arjun Vasant, Ashish M. Kamat, Girish S. Kulkarni, et al.. (2021). Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin: Extended follow-up of KEYNOTE-057 cohort A.. Journal of Clinical Oncology. 39(6_suppl). 451–451. 7 indexed citations
9.
Galsky, Matt D., Andrea Necchi, Neal D. Shore, et al.. (2020). Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905.. Journal of Clinical Oncology. 38(6_suppl). TPS593–TPS593. 2 indexed citations
10.
Balar, Arjun Vasant, Ashish M. Kamat, Girish S. Kulkarni, et al.. (2020). Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057.. Journal of Clinical Oncology. 38(15_suppl). 5041–5041. 23 indexed citations
11.
Kamat, Ashish M., Neal D. Shore, Noah M. Hahn, et al.. (2019). Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study.. Journal of Clinical Oncology. 37(15_suppl). TPS4591–TPS4591. 3 indexed citations
12.
Wit, Ronald de, Arjun Vasant Balar, Ashish M. Kamat, et al.. (2019). MP43-01 PHASE 2 KEYNOTE-057 STUDY: PEMBROLIZUMAB FOR PATIENTS WITH HIGH-RISK NON–MUSCLE INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN. The Journal of Urology. 201(Supplement 4). 4 indexed citations
13.
Wit, Ronald de, Girish S. Kulkarni, Edward Uchio, et al.. (2019). Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057.. Journal of Clinical Oncology. 37(15_suppl). 4530–4530. 4 indexed citations
14.
Balar, Arjun Vasant, Girish S. Kulkarni, Edward Uchio, et al.. (2019). Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).. Journal of Clinical Oncology. 37(7_suppl). 350–350. 80 indexed citations
15.
16.
Bellmunt, Joaquim, Ronald de Wit, David J. Vaughn, et al.. (2018). Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).. Journal of Clinical Oncology. 36(6_suppl). 410–410. 21 indexed citations
17.
Fradet, Yves, Joaquim Bellmunt, Ronald de Wit, et al.. (2018). Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.. Journal of Clinical Oncology. 36(15_suppl). 4521–4521. 4 indexed citations
18.
Nam, Kijoeng, et al.. (2017). Logistic Regression Likelihood Ratio Test Analysis for Detecting Signals of Adverse Events in Post-market Safety Surveillance. Journal of Biopharmaceutical Statistics. 27(6). 990–1008. 13 indexed citations
19.
Kamat, Ashish M., Joaquim Bellmunt, Toni K. Choueiri, et al.. (2016). KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC).. Journal of Clinical Oncology. 34(15_suppl). TPS4576–TPS4576. 10 indexed citations
20.
Nam, Kijoeng, Hong-Mo Je, & Seungjin Choi. (2005). Fast stochastic neighbor embedding: a trust-region algorithm. 15. 123–128. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José Portillo Breakdown of academic impact, for papers by Vipulkumar Dadhania Breakdown of academic impact, for papers by A P van der Meijden Breakdown of academic impact, for papers by Catalona Wj Breakdown of academic impact, for papers by J.L.J. Vriesema Breakdown of academic impact, for papers by Spasenija Savic-Prince Breakdown of academic impact, for papers by Ch. Bouffioux Breakdown of academic impact, for papers by Sameh Shamaa Breakdown of academic impact, for papers by Timothy Brennan Breakdown of academic impact, for papers by Cheryl L. Hayden
Rankless by CCL
2026